Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13938233 | 0.93 | ADORA1 (0.79) | ADORA1SLC6A3 | |
| SCHEMBL3699454 | 0.92 | ADORA1 (0.81) | ADORA1SLC6A3 | |
| SCHEMBL12869980 | 0.92 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL13937445 | 0.92 | ADORA1 (0.77) | ADORA1SLC6A3 | |
| SCHEMBL13938560 | 0.92 | ADORA1 (0.77) | ADORA1SLC6A3 | |
| Hydrochloric Acid SCHEMBL3698557 | 0.92 | ADORA1 (0.79) | ADORA1SLC6A3 | |
| SCHEMBL13945016 | 0.91 | ADORA1 (0.76) | ADORA1SLC6A3 | |
| SCHEMBL7642574 | 0.91 | ADORA1 (0.78) | ADORA1SLC6A3 | |
| SCHEMBL7669582 | 0.90 | ADORA1 (0.75) | ADORA1SLC6A3 | |
| SCHEMBL7646632 | 0.90 | ADORA1 (0.75) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556856-B1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | BAYER IP GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-8618119-B2 | Fused cyanopyridines and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-2556831-A1 | 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine-6-carbonitriles as Adenosin Receptor Ligands for Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556856-A1 | 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2234980-B1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER IP GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
| WO-2009080198-A1 | FUSED CYNOPRYRIDINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | TNNI3, QDPR, RYR2 | ADORA1 2751/4885SLC6A3 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.